Cases & Deals

  • Home
  • Practices
  • NGM Bio develops global patent portfolio for therapeutic antibodies for the treatment of cancer and tumors

Share

NGM Bio develops global patent portfolio for therapeutic antibodies for the treatment of cancer and tumors

April 2024

Client(s) NGM Biopharmaceuticals, Inc.

Jones Day represents NGM Biopharmaceuticals, Inc. in the development of a global patent portfolio for therapeutic antibodies for the treatment of cancer and tumors, including NGM707, a dual ILT2/ILT4 antagonist antibody; NGM831, an ILT3 antagonist antibody; and NGM438, a LAIR1 antagonist antibody.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.